164 related articles for article (PubMed ID: 21778065)
1. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
2. Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Hsu PH; Chiu DC; Wu KL; Lee PS; Jan JT; Cheng YE; Tsai KC; Cheng TJ; Fang JM
Eur J Med Chem; 2018 Jun; 154():314-323. PubMed ID: 29843102
[TBL] [Abstract][Full Text] [Related]
3. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Magano J
Chem Rev; 2009 Sep; 109(9):4398-438. PubMed ID: 19537777
[No Abstract] [Full Text] [Related]
4. Antiviral drugs for influenza 2012-2013.
Med Lett Drugs Ther; 2012 Dec; 54(1405):97-8. PubMed ID: 23223245
[No Abstract] [Full Text] [Related]
5. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
[TBL] [Abstract][Full Text] [Related]
6. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
8. Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.
Miller JM; Dahan A; Gupta D; Varghese S; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1223-34. PubMed ID: 20536260
[TBL] [Abstract][Full Text] [Related]
9. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Farrukee R; Mosse J; Hurt AC
Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1135-45. PubMed ID: 24093683
[TBL] [Abstract][Full Text] [Related]
10. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Yamashita M; Tomozawa T; Kakuta M; Tokumitsu A; Nasu H; Kubo S
Antimicrob Agents Chemother; 2009 Jan; 53(1):186-92. PubMed ID: 18955520
[TBL] [Abstract][Full Text] [Related]
11. A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
Somasundaram B; Fee CJ; Fredericks R; Watson AJ; Fairbanks AJ; Hall RJ
J Mol Recognit; 2015 Sep; 28(9):521-7. PubMed ID: 25727669
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
[TBL] [Abstract][Full Text] [Related]
13. Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Haldar J; Chen J; Tumpey TM; Gubareva LV; Klibanov AM
Biotechnol Lett; 2008 Mar; 30(3):475-9. PubMed ID: 17972018
[TBL] [Abstract][Full Text] [Related]
14. [Neuraminidase inhibitor].
Kaji M
Nihon Rinsho; 2000 Nov; 58(11):2293-8. PubMed ID: 11225320
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
Honda T; Kubo S; Masuda T; Arai M; Kobayashi Y; Yamashita M
Bioorg Med Chem Lett; 2009 Jun; 19(11):2938-40. PubMed ID: 19414262
[TBL] [Abstract][Full Text] [Related]
16. Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors.
Mohr PG; Geyer H; McKimm-Breschkin JL
Antiviral Res; 2011 Jul; 91(1):20-2. PubMed ID: 21549758
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
19. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Yamashita M
Antivir Chem Chemother; 2010; 21(2):71-84. PubMed ID: 21107016
[TBL] [Abstract][Full Text] [Related]
20. Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.
Niikura M; Bance N; Mohan S; Mario Pinto B
Antiviral Res; 2011 Jun; 90(3):160-3. PubMed ID: 21443905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
